Clinical Trial Update: Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC) [Phase 2, Phase 3]

View source ↗

Summary

This is a Phase 2/Phase 3 clinical trial (MODIFI-CRC) evaluating node-sparing short-course radiotherapy with chemotherapy, bevacizumab, and a PD-1 inhibitor in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-1 inhibitor

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Immune Checkpoint Therapy, Radiotherapy | Phase 2, Phase 3 | Status: RECRUITING